Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2016

View Archived Issues

Shanghai Institute Materia Medica develops tyrosine kinase inhibitors

ExpreS2ion and Abivax enter collaboration on Ebola prophylaxis and treatment program

Medicenna Biopharma begins phase II study of MDNA-55

European Commission grants conditional approval to Ocaliva

KemPharm reports positive results from phase I proof-of-concept study of d-MPH prodrug

ALS symptoms deteriorate after stopping ibudilast treatment in clinical trial

AN-13762 described as representing a new class of antimalarial

Novel therapeutic targets described at the Society for Neuroscience Annual Meeting

Concert Pharmaceuticals completes phase I study of JAK inhibitor for alopecia areata

TPC-064: a novel mutant-selective EGFR inhibitor

vTv Therapeutics reports topline data from phase II trial of TTP-273 in type 2 diabetes

Kiadis obtains U.K. approvals for phase I/II trial of ATIR-201 for thalassemia

FDA gives orphan drug designation to nintedanib in mesothelioma

Encouraging results reported from tolerability proof-of-concept study of KarXT

Epigenetic compound CTI-309 shows promise as Alzheimer's disease candidate

TSRI, Icahn School of Medicine and UPenn patent nAChR modulators

Bicycle Therapeutics collaborates with Cancer Research UK to study BT-1718

Harvard and Evotec divulge novel bacterial glycosyl transferase inhibitors

Merck & Co. discovers soluble guanylate cyclase activators

FDA approves Eucrisa for atopic dermatitis

Principia Biopharma patents new FGFR inhibitors

Chong Kun Dang Holdings divulges new histone deacetylase inhibitors

Hologic to divest blood screening business to Grifols

argenx initiates phase I/II study of ARGX-110 with azacitidine in newly diagnosed AML

Third Rock Ventures launches Goldfinch Bio with a focus on therapies for kidney disease

Biogen files for Japanese approval of nusinersen for SMA

Lonza set to acquire Capsugel

CM-4620 receives EMA orphan designation for acute pancreatitis

Gamunex-C granted FDA orphan status for myasthenia gravis

Polatuzumab vedotin given U.S. orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...